These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32248375)

  • 21. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort.
    Jansson H; Cornillet M; Björkström NK; Sturesson C; Sparrelid E
    Eur J Surg Oncol; 2020 May; 46(5):804-810. PubMed ID: 31848078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
    Song A; Eo W; Lee S
    World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between tumour stage, systemic inflammation, body composition and survival in patients with colorectal cancer.
    McSorley ST; Black DH; Horgan PG; McMillan DC
    Clin Nutr; 2018 Aug; 37(4):1279-1285. PubMed ID: 28566220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores.
    Dolan RD; McSorley ST; Park JH; Watt DG; Roxburgh CS; Horgan PG; McMillan DC
    Br J Cancer; 2018 Jul; 119(1):40-51. PubMed ID: 29789606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated inflammatory parameters and inflammation scores are associated with poor prognosis in patients undergoing pulmonary metastasectomy for colorectal cancer.
    Ghanim B; Schweiger T; Jedamzik J; Glueck O; Glogner C; Lang G; Klepetko W; Hoetzenecker K
    Interact Cardiovasc Thorac Surg; 2015 Nov; 21(5):616-23. PubMed ID: 26242317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative change of modified Glasgow prognostic score after stenting predicts the long-term outcomes of obstructive colorectal cancer.
    Sato R; Oikawa M; Kakita T; Okada T; Abe T; Yazawa T; Tsuchiya H; Akazawa N; Sato M; Ohira T; Harada Y; Okano H; Ito K; Ohuchi N; Tsuchiya T
    Surg Today; 2020 Mar; 50(3):232-239. PubMed ID: 31407166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aspects of survival from colorectal cancer in Denmark.
    Iversen LH
    Dan Med J; 2012 Apr; 59(4):B4428. PubMed ID: 22459726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Predictive and Prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) in advanced gastric cancer patients treated with neoadjuvant chemotherapy].
    Cui Y; Li J; Cao YH; Liu MY; Shi ZX; Gao TH
    Zhonghua Zhong Liu Za Zhi; 2017 Mar; 39(3):195-200. PubMed ID: 28316218
    [No Abstract]   [Full Text] [Related]  

  • 29. Does the modified Glasgow Prognostic Score (mGPS) have a prognostic role in esophageal cancer?
    Walsh SM; Casey S; Kennedy R; Ravi N; Reynolds JV
    J Surg Oncol; 2016 Jun; 113(7):732-7. PubMed ID: 27004839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective study of the role of inflammation in renal cancer.
    Qayyum T; McArdle PA; Lamb GW; Going JJ; Orange C; Seywright M; Horgan PG; Oades G; Aitchison MA; Edwards J
    Urol Int; 2012; 88(3):277-81. PubMed ID: 22377628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between patient physiology, the systemic inflammatory response and survival in patients undergoing curative resection of colorectal cancer.
    Richards CH; Leitch EF; Horgan PG; Anderson JH; McKee RF; McMillan DC
    Br J Cancer; 2010 Oct; 103(9):1356-61. PubMed ID: 20877354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of chemotherapy and operation in patients with colorectal neuroendocrine carcinoma.
    Wu Z; Yu D; Zhao S; Gao P; Song Y; Sun Y; Chen X; Wang Z
    J Surg Res; 2018 May; 225():54-67. PubMed ID: 29605035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Burden of Modified Glasgow Prognostic Scale in Colorectal Cancer.
    Okugawa Y; Shirai Y; Toiyama Y; Saigusa S; Hishida A; Yokoe T; Tanaka K; Tanaka M; Yasuda H; Fujikawa H; Hiro J; Kobayashi M; Araki T; Inoue Y; McMillan DC; Kusunoki M; Miki C
    Anticancer Res; 2018 Mar; 38(3):1599-1610. PubMed ID: 29491091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relationship between computed tomography-derived body composition, systemic inflammatory response, and survival in patients undergoing surgery for colorectal cancer.
    Dolan RD; Almasaudi AS; Dieu LB; Horgan PG; McSorley ST; McMillan DC
    J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):111-122. PubMed ID: 30460764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical value of C-reactive protein and its association with tumour location in patients undergoing curative surgery for colorectal cancer - a ScotScan collaborative study.
    Fuglestad AJ; Meltzer S; Ree AH; McMillan DC; Park JH; Kersten C
    Acta Oncol; 2022 Oct; 61(10):1248-1255. PubMed ID: 36068730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
    Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
    BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microenvironment, systemic inflammatory response and tumor markers considering consensus molecular subtypes of colorectal cancer.
    Jakab A; Patai ÁV; Darvas M; Tormássi-Bély K; Micsik T
    Pathol Oncol Res; 2024; 30():1611574. PubMed ID: 38645565
    [No Abstract]   [Full Text] [Related]  

  • 39. Determinants of lymph node count and positivity in patients undergoing surgery for colon cancer.
    Dolan RD; McSorley ST; Horgan PG; McMillan DC
    Medicine (Baltimore); 2018 Mar; 97(13):e0185. PubMed ID: 29595652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.
    Ishizuka M; Nagata H; Takagi K; Kubota K
    Ann Surg; 2009 Aug; 250(2):268-72. PubMed ID: 19638907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.